NICE TAs

21/10/2020

TA655: Nivolumab for advanced squamous non-small-cell lung cancer after chemotherapy

20/10/2020

TA457: Carfilzomib for previously treated multiple myeloma

Evidence-based recommendations on carfilzomib (Kyprolis) for treating multiple myeloma in adults.

14/10/2020

TA654: Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer

14/10/2020

TA653: Osimertinib for treating EGFR T790M mutation-positive advanced non-small-cell lung cancer

12/10/2020

TA604: Idelalisib for treating refractory follicular lymphoma

12/10/2020

TA626: Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure

12/10/2020

TA631: Fremanezumab for preventing migraine

12/10/2020

TA630: Larotrectinib for treating NTRK fusion-positive solid tumours

12/10/2020

TA633: Ustekinumab for treating moderately to severely active ulcerative colitis

12/10/2020

TA639: Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer

12/10/2020

TA638: Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer

12/10/2020

TA649:Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma

01/10/2020

TA651: Naldemedine for treating opioid-induced constipation

02/09/2020

TA645: Avelumab with axitinib for untreated advanced renal cell carcinoma

19/08/2020

NG101: Early and locally advanced breast cancer: diagnosis and management

19/08/2020

TA135: Pemetrexed for the treatment of malignant pleural mesothelioma

19/08/2020

TA116: Gemcitabine for the treatment of metastatic breast cancer

19/08/2020

TA124: Pemetrexed for the treatment of non-small-cell lung cancer

18/08/2020

TA127: Natalizumab for the treatment of adults with highly active relapsing–remitting multiple sclerosis

18/08/2020

TA134: Infliximab for the treatment of adults with psoriasis